Provide 'partial list' of over the counter drugs to doctors: HC to Centre

Image
Press Trust of India New Delhi
Last Updated : Jul 03 2019 | 6:05 PM IST

The Delhi High Court Wednesday directed the Centre to provide a "partial list" of over the counter (OTC) drugs to doctors and pharmacists by September 12.

A bench of Chief Justice D N Patel and Justice C Hari Shankar issued the direction on a PIL initiated by the court on its own after receiving a letter from a doctor for formulation of a law relating to OTC drugs and preparation of a list of such medication.

"You (Centre) already know which are the scheduled drugs. So, collate the remaining medicines into a list and provide it to them," the court told the central government standing counsel Ajay Digpaul, representing the health ministry.

Digpaul told the court that a sub-committee constituted by the 52nd Drugs Consultative Committee (DCC) has already examined the issue raised in the PIL and has given a report on several aspects regarding OTC drugs including its definition, basic characteristics, manufacturing, labelling, distribution, sale and pricing.

He said that the sub-committee's report was being examined by another sub-committee which shall give its final report in three months to the DCC which will forward it to the Drugs Technical Advisory Board (DTAB) for further consideration.

However, the bench was not impressed and said that going by the status report shown to it, the government appears to "have not understood what they (doctors) are asking for".

"As things stand today, it is not that difficult to provide a list of OTC drugs," the court said, directing that a "partial list" be provided to doctors before the next date of hearing on September 12.

The PIL was initiated by the court after receiving a letter from Dr K K Aggarwal, a Padma Shree awardee and the National President of Heart Care Foundation of India (HCFI), seeking formulation of a law regarding OTC drugs and preparation of a list of such medicines in India.

Aggarwal, who has been appointed as amicus curiae to assist the court in the matter, has contended that the list of OTC drugs would help to advance consumer health because it would allow people to treat or manage many health conditions conveniently and successfully.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jul 03 2019 | 6:05 PM IST

Next Story